India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life Sciences (opens original article in a new tab)

India's CDMO industry is gaining traction as global pharmaceutical companies shift manufacturing away from China, with Sai Life Sciences expanding capacity to capitalize on this trend.

• Global pharmaceutical companies are diversifying manufacturing away from China due to regulatory scrutiny.
• Indian CDMO industry is emerging as a preferred alternative for global drugmakers.
• Sai Life Sciences plans to invest ₹1,100-1,300 crore in capacity expansion by FY27.